<Doctoral Thesis>
The IL-13/periostin/IL-24 pathway causes epidermal barrier dysfunction in allergic skin inflammation
Creator | |
---|---|
Examiner | |
Language | |
Academic Year Conferred | |
Conferring University | |
Degree | |
Degree Type | |
Access Rights | |
Related DOI | |
Abstract | Background: Barrier dysfunction is an important feature of atopic dermatitis (AD) in which IL-4 and IL-13, signature type 2 cytokines, are involved. Periostin, a matricellular protein induced by IL-4 ...or IL-13, plays a crucial role in the onset of allergic skin inflammation, including barrier dysfunction. However, it remains elusive how periostin causes barrier dysfunction downstream of the IL-13 signal. Methods: We systematically identified periostin-dependent expression profile using DNA microarrays. We then investigated whether IL-24 downregulates filaggrin expression downstream of the IL-13 signals and whether IL-13-induced IL-24 expression and IL-24-induced downregulation of filaggrin expression are dependent on the JAK/STAT pathway. To build on the significance of in vitro findings, we investigated expression of IL-24 and activation of STAT3 in mite-treated mice and in AD patients. Results: We identified IL-24 as an IL-13-induced molecule in a periostin-dependent manner. Keratinocytes are the main IL-24-producing tissue-resident cells stimulated by IL-13 in a periostin-dependent manner via STAT6. IL-24 significantly downregulated filaggrin expression via STAT3, contributing to barrier dysfunction downstream of the IL-13/periostin pathway. Wild-type mite-treated mice showed significantly enhanced expression of IL-24 and activation of STAT3 in the epidermis, which disappeared in both STAT6-deficient and periostin-deficient mice, suggesting that these events are downstream of both STAT6 and periostin. Moreover, IL-24 expression was enhanced in the epidermis of skin tissues taken from AD patients. Conclusions: The IL-13/periostin pathway induces IL-24 production in keratinocytes, playing an important role in barrier dysfunction in AD.show more |
Hide fulltext details.
File | FileType | Size | Views | Description |
---|---|---|---|---|
med3161_abstract | 145 KB | 1,372 | 要旨 | |
med3161_review | 162 KB | 467 | 審査結果要旨 |
Details
Record ID | |
---|---|
Peer-Reviewed | |
Rights | |
Related PubMed ID | |
Report Number | |
Number of Diploma | |
Granted Date | |
Date Accepted | |
Faculty | |
Created Date | 2018.11.05 |
Modified Date | 2018.11.27 |